Transplant immunosuppressant agents and their role in autoimmune rheumatic diseases

Current Opinion in Rheumatology

Volumn 15, Issue 3, 2003, Pages 219-225

  Mayer, Dean F ^a   Kushwaha, Sudhir S ^a,b  

^a MAYO CLINIC   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; PREDNISONE; RAPAMYCIN; TACROLIMUS;

AUTOIMMUNE DISEASE; BEHCET DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DERMATOMYOSITIS; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; FEVER; FIBROSING ALVEOLITIS; GASTROINTESTINAL TOXICITY; GRAFT REJECTION; HUMAN; HYPERSENSITIVITY; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DISEASE; KIDNEY FAILURE; LEUKOCYTOCLASTIC VASCULITIS; LUNG DISEASE; LUNG TUBERCULOSIS; LUPUS ERYTHEMATOSUS NEPHRITIS; MULTICENTER STUDY; NEPHROTOXICITY; NEUROPATHIC PAIN; NONHUMAN; POLYMYOSITIS; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SCLERODERMA; SIDE EFFECT; SKIN DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS; THORAX PAIN; TREATMENT OUTCOME; WEGENER GRANULOMATOSIS;

AUTOIMMUNE DISEASES; AZATHIOPRINE; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ISOXAZOLES; MALE; MYCOPHENOLIC ACID; RHEUMATIC DISEASES; SEVERITY OF ILLNESS INDEX; SIROLIMUS; TACROLIMUS; TRANSPLANTS; TREATMENT OUTCOME;

EID: 0037732692     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-200305000-00008     Document Type: Review

References (59)

1. Cardenas ME, Zhu D, Heitman J: Molecular mechanisms of immunosuppression by cyclosporine, FK-506 and rapamycin. Curr Opin Nephrol Hypertens 1995, 4:472-477.
2. Senel F, Kahan BD: New small molecule immunosuppressive agents. In Immunosuppression in Transplantation. Edited by Ginns LC, Cosimi AB, Morris PJ. Boston: Blackwell Science; 1999:67-84.
3. Brazelton TR, Morris RE: Molecular mechanisms of action of new xenobiotic immunosuppressive drugs: tacrolimus (FK506), sirolimus (rapamycin), mycophenolate mofetil and leflunomide. Curr Opin Immunol 1996, 8:710-720.
4. Taylor DO, Barr ML, Meiser BM, et al.: Suggested guidelines for the use of tacrolimus in cardiac transplant recipients. J Heart Lung Transplant 2001, 20:734-738.
5. Onsager DR, Canver CC, Jahania MS, et al.: Efficacy of tacrolimus in the treatment of refractory rejection in heart and lung transplant recipients. J Heart Lung Transplant 1999, 18:448-455.
6. Garrity ER Jr, Hertz MI, Trulock EP, et al.: Suggested guidelines for the use of tacrolimus in lung-transplant recipients. J Heart Lung Transplant 1999, 18:175-176.
7. Gruessner RW: Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group. Clin Transplant 1997, 11:299-312.
8. Gremillion RB, Posever JO, Manek N, et al.: Tacrolimus (FK 506) in the treatment of severe, refractory rheumatoid arthritis: Initial experience in 12 patients. J Rheumatol 1999, 26:2332-2336.
9. Furst DE, Saag K, Fleischmann MR, et al.: Efficacy of tacrolimus in rheumatoid arthritis patients who have been treated unsuccessfully with methotrexate: a six-month, double blind, randomized, dose-ranging study. Arthritis Rheum 2002, 46:2020-2028. This multicenter, randomized, placebo-controlled trial examined the use of tacrolimus in patients who were either intolerant of methotrexate or resistant to it. A dose-dependent response was observed, with greater effectiveness and increased toxicity apparent at higher doses.
10. Oddis CV, Sciurba FC, Elmagd KA, et al.: Tacrolimus in refractory polymyositis with interstitial lung disease. Lancet 1999, 353:1762-1763.
11. Oddis CV: Current approach to the treatment of polymyositis and dermatomyositis. Curr Opin Rheumatol 2000, 12:492-497.
12. Duddridge M, Powell RJ: Treatment of severe and difficult cases of systemic lupus erythematosus with tacrolimus. A report of three cases. Ann Rheum Dis 1997, 56:690-692.
13. Morton SJ, Powell PJ: Cyclosporin and tacrolimus: their use in a routine clinical setting for scleroderma. Rheumatology 2000, 39:865-869.
14. Sloper CM, Powell PJ, Dua HS: Tacrolimus (FK506) in the treatment of posterior uveitis refractory to cyclosporine. Ophthalmology 1999, 106:723-728.
15. Kilmartin DJ, Forrester JV, Dick AD: Tacrolimus (FK506) in failed cyclosporin A therapy in endogenous posterior uveitis. Ocul Immunol Inflamm 1998, 6:101-109.
16. Pilmore HL, Faire B, Dittmer I: Tacrolimus for treatment of gout in renal transplantation: two case reports and review of the literature. Transplantation 2001, 72:1703-1705.
17. Radovancevic B, El-Sabrout R, Thomas C, et al.: Rapamycin reduces rejection in heart transplant recipients. Transplant Proc 2001, 33:3221-3222.
18. Winters GL, McManus BM: Consistencies and controversies in the application of the International Society for Heart and Lung Transplantation working formulation for heart transplant biopsy specimens. J Heart Lung Transplant 1996, 15:728-735.
19. Odorico JS, Sollinger HW: Technical and immunosuppressive advances in transplantation for insulin-dependent diabetes mellitus. World J Surg 2002, 26:194-211.
20. Nishida S, Pinna A, Verzaro R, et al.: Sirolimus (rapamycin)-based rescue treatment following chronic rejection after liver transplantation. Transplant Proc 2001, 33:1495.
21. Migita K, Eguchi K, Aoyagi T, et al.: The effects of the immunosuppressant rapamycin on the growth of rheumatoid arthritis (RA) synovial fibroblast. Clin Exp Immunol 1996, 104:86-91.
22. Migita K, Eguchi K, Ichinose Y, et al.: Effects of rapamycin on apoptosis of rheumatoid synovial cells. Clin Exp Immunol 1997, 108:199-203.
23. Warner LM, Adams LM, Sehgal SN: Rapamycin prolongs survival and arrests pathophysiologic changes in murine systemic lupus erythematosus. Arthritis Rheum 1994, 37:289-297.
24. Constantinescu AR, Liang M, Laskow DA: Sirolimus lowers myeloperoxidase and p-ANCA titers in a pediatric patient before kidney transplantation. Am J Kidney Dis 2002, 40:407-410. This article describes a patient with microscopic polyangiitis who experienced decreasing perinuclear antineutrophil cytoplasmic antibody titers and improved clinical symptoms when treated with rapamycin before renal transplantation.
25. Hardinger KL, Cornelius LA, Trulock EP III, et al.: Sirolimus-induced leukocytoclastic vasculitis. Transplantation 2002, 74:739-743.
26. Rigotti P, Cadrobbi R, Baldan N, et al.: Mycophenolate mofetil (MMF) versus azathioprine (AZA) in pancreas transplantation: a single-center experience. Clin Nephrol 2000, 53:52-54.
27. Busca A, Saroglia EM, Lanino E, et al.: Mycophenolate mofetil (MMF) as therapy for refractory chronic GVHD (cGVHD) in children receiving bone marrow transplantation. Bone Marrow Transplant 2000, 25:1067-1071.
28. Basara N, Blau WI, Kiehl MG, et al.: Mycophenolate mofetil for the prophylaxis of acute GVHD in HLA-mismatched bone marrow transplant patients. Clin Transplant 2000, 14:121-126.
29. Dooley MA, Cosio FG, Nachman PH, et al.: Mycophenolate mofetil therapy in lupus nephritis: clinical observations. J Am Soc Nephrol 1999, 10:833-839.
30. Wallman L, Stewart G, Chapman J, et al.: Mycophenolate mofetil for treatment of refractory lupus nephritis: four pilot cases. Aust N Z J Med 2000, 30:712-715.
31. Hu W, Liu Z, Chen H, et al.: Mycophenolate mofetil vs cyclophosphamide therapy for patients with diffuse proliferative lupus nephritis. Chin Med J (Engl) 2002, 115:705-709.
32. Chan TM, Li FK, Tang CS, et al.: Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med 2000, 343:1156-1162.
33. Chan TM, Wong RWS, Lau CS, et al.: Prolonged follow-up of patients with diffuse proliferative lupus nephritis treated with prednisolone and mycophenolate mofetil [abstract]. J Am Soc Nephrol 2001, 12:1010A. This abstract describes the long-term follow-up of the earlier study [32] comparing a mycophenolate mofetil regimen with a cyclophosphamide regimen in the treatment of World Health Organization class IV lupus nephritis. At 36 months, the rate of relapse was higher in the group treated with mycophenolate mofetil.
34. Mok CO, Lai KN: Mycophenolate mofetil in lupus glomerulonephritis. Am J Kidney Dis 2002, 40:447-457. This article provides a comprehensive, up-to-date review of the evidence for using mycophenolate mofetil to treat lupus nephritis.
35. Nowack R, Gobel U, Klooker P, et al.: Mycophenolate mofetil for maintenance therapy of Wegener's granulomatosis and microscopic polyangiitis: a pilot study in 11 patients with renal involvement. J Am Soc Nephrol 1999, 10:1965-1971.
36. Worm M, Sterry W, Kolde G: Mycophenolate mofetil is effective for maintenance therapy of hypocomplementaemic urticarial vasculitis. Br J Dermatol 2000, 143:1324.
37. Adler YD, Mansmann U, Zouboulis CC: Mycophenolate mofetil is ineffective in the treatment of mucocutaneous Adamantiades-Behçet's disease. Dermatology 2001, 203:322-324.
38. Schffeider C, Gold R, Schafers M, et al.: Mycophenolate mofetil in the therapy of polymyositis associated with a polyautoimmune syndrome. Muscle Nerve 2002, 25:286-288. Manifestations of polymyositis improved with mycophenolate mofetil administration in this patient.
39. Gelber AC, Nousari HC, Wigley FM: Mycophenolate mofetil in the treatment of severe skin manifestations of dermatomyositis: a series of 4 cases. J Rheumatol 2000, 27:1542-1545.
40. Tausche AK, Meurer M: Mycophenolate mofetil for dermatomyositis. Dermatology 2001, 202:341-343.
41. Mowzoon N, Sussman A, Bradley WG: Mycophenolate (CellCept) treatment of myasthenia gravis, chronic inflammatory polyneuropathy and inclusion body myositis. J Neurol Sci 2001, 185:119-122.
42. Schiff MH, Goldblum R, Rees MMC: 2-Morpholino-ethyl mycophenolic acid (ME-MPA) in the treatment of refractory rheumatoid arthritis (RA). Arthritis Rheum 1990, 33:S155.
43. Grundmann-Kollmann M, Mooser G, Schraeder P, et al.: Treatment of chronic plaque-stage psoriasis and psoriatic arthritis with mycophenolate mofetit. J Am Acad Dermatol 2000, 42:835-837.
44. Stratton RJ, Wilson H, Black CM: Pilot study of anti-thymocyte globulin plus mycophenolate mofetil in recent-onset diffuse scleroderma. Rheumatology (Oxford) 2001, 40:84-88. Combination therapy with antithymocyte globulin and mycophenolate mofetil may have alleviated some symptoms of scleroderma, but there were considerable adverse events in the trial.
45. Olsen NJ, Strand V, Kremer JM: Leflunomide for the treatment of rheumatoid arthritis. Bull Rheum Dis 1999, 48:1-4.
46. Remer CF, Weisman MH, Wallace DJ: Benefits of leflunomide in systemic lupus erythematosus: a pilot observational study. Lupus 2001, 10:480-483. This uncontrolled pilot study suggests the possible effectiveness of leflunomide in treating manifestations of lupus.
47. D'Silva M, Candinas D, Achilleos O, et al.: The immunomodulatory effects of a novel agent, leflunomide, in rat cardiac allotransplantation. Transpl Int 1994, 7(suppl 1):S378-S380.
48. Guo Z, Chong AS, Shen J, et al.: In vivo effects of leflunomide on normal pancreatic islet and syngeneic islet graft function. Transplantation 1997, 63:716-721.
49. Adams BF, Berry GJ, Huang X, et al.: Immunosuppressive therapies for the prevention and treatment of obliterative airway disease in heterotopic rat trachea allografts. Transplantation 2000, 69:2260-2266.
50. Williams JW, Mital D, Chong A, et al.: Experiences with leflunomide in solid organ transplantation. Transplantation 2002, 73:358-366. The authors' experience with leflunomide in liver and kidney transplant recipients is detailed. Their experience suggests safety and efficacy in these settings.
51. Temekonidis TI, Georgiadis AN, Alamanos Y, et al.: Infliximab treatment in combination with cyclosporin A in patients with severe refractory rheumatoid arthritis. Ann Rheum Dis 2002, 61:822-825. Patients who could not tolerate methotrexate received cyclosporine and infliximab. The combination was effective and generally well tolerated.
52. Tam LS, Li EK, Szeto CC, et al.: Treatment of membranous lupus nephritis with prednisone, azathioprine and cyclosporin A. Lupus 2001, 10:827-829. Most patients with World Health Organization class Va or Vb lupus nephritis responded to this combination regimen.
53. Filaci G, Cutolo M, Basso M, et al.: Long-term treatment of patients affected by systemic sclerosis with cyclosporin A. Rheumatology (Oxford) 2001, 40:1431-1432. Some manifestations of scleroderma appeared to improve during cyclosporine therapy in this small series of patients.
54. Ghez D, Westeel PF, Henry I, et al.: Control of a relapse and induction of long-term remission of Wegener's granulomatosis by cyclosporine. Am J Kidney Dis 2002, 40:E6. Monotherapy with cyclosporine successfully controlled disease activity and maintained remission in a case of relapsing Wegener granulomatosis.
55. Raman V, Kim J, Sharkey A, et al.: Response of refractory Kawasaki disease to pulse steroid and cyclosporin A therapy. Pediatr Infect Dis J 2001, 20:635-637. A patient with Kawasaki disease refractory to intravenous IgG was successfully treated with corticosteroid and cyclosporine.
56. Houssiau FA, Vasconcelos C, D'Cruz D, et al.: Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 2002, 46:2121-2131. Alternative dosing regimens of cyclophosphamide for the treatment of WHO class III, IV, Vc, or Vd were investigated in this multicenter, randomized trial. The results between the two groups were statistically similar.
57. Gladstone DE, Prestrud AA, Pradhan A, et al.: High-dose cyclophosphamide for severe systemic lupus erythematosus. Lupus 2002, 11:405-410. Myelosuppressive doses of cyclophosphamide improved lupus disease activity scores but required substantial supportive care.
58. Lorenzi AR, Johnson AH, Davies G, et al.: Gastric antral vascular ectasia in systemic sclerosis: complete resolution with methylprednisolone and cyclophosphamide. Ann Rheum Dis 2001, 60:796-798. An unexpected finding of scleroderma-related gastric vascular ectasia resolving with cyclophosphamide and corticosteroid administration. No other similar cases have been published.
59. Ligtenberg G, Grootscholten CM, Derksen RHWM, et al.: Cyclophosphamide pulse therapy versus azathioprine and pulse methylprednisolone pulses in proliferative lupus nephritis: first results of a randomized, prospective multicenter study. Abstract presented at The American Society of Nephrology, 35th Annual Meeting and Scientific Exposition, 2002. Preliminary data recently presented from a multicenter randomized trial suggest that an azathioprine/corticosteroid regimen may be an effective and safe alternative to traditional cyclophosphamide/corticosteroid regimens in the treatment of proliferative lupus nephritis. Long-term data continue to be collected.